FDA Approves AbbVie's JUVMO, First Selective D1/D5 Agonist for Parkinson's, With US Launch Set for October

SentiSense · Published Sep 28, 2026, 8:00 AM ET · Updated Sep 28, 2026, 6:54 PM ET

The FDA approved AbbVie's JUVMO (tavapadon) on September 28, 2026, the first and only selective D1/D5 receptor agonist for adults with Parkinson's dis...